Embla Medical hf. (CPH:EMBLA)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 11.40B |
| Revenue (ttm) | 5.91B |
| Net Income (ttm) | 530.09M |
| Shares Out | 426.87M |
| EPS (ttm) | 1.24 |
| PE Ratio | 21.51 |
| Forward PE | 17.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 788,273 |
| Average Volume | 227,232 |
| Open | 27.55 |
| Previous Close | 27.65 |
| Day's Range | 26.60 - 27.55 |
| 52-Week Range | 25.00 - 37.90 |
| Beta | 0.48 |
| RSI | 38.68 |
| Earnings Date | Apr 28, 2026 |
About Embla Medical
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides os... [Read more]
Financial Performance
In 2025, Embla Medical's revenue was $928.69 million, an increase of 8.63% compared to the previous year's $854.89 million. Earnings were $83.34 million, an increase of 22.05%.
Financial numbers in USD Financial StatementsNews
Embla Medical Earnings Call Transcript: Q1 2026
Q1 2026 saw 15% revenue growth (4% organic), stable margins despite tariffs and FX, and 21% bottom-line growth. Guidance for 5%-8% organic growth and 20%-22% EBITDA margin is reiterated, with segment strength in Prosthetics and neuro-orthotics and recovery expected in Patient Care.
Embla Medical Earnings Call Transcript: Q1 2026
Q1 2026 saw 15% reported sales growth and strong performance in Prosthetics and Neuro Orthotics, while EBITDA margin declined to 17% due to FX and tariffs. Full-year guidance of 5%-8% organic growth and 20%-22% EBITDA margin is maintained.
Embla Medical Transcript: Life Science-dagen 2026
A global leader in mobility solutions is driving growth through innovation, acquisitions, and expanding access to advanced prosthetics and neuro-orthotics. Key growth comes from functional trade-up, recurring sales, and new market penetration, while challenges include reimbursement, tariffs, and geopolitical risks.
Embla Medical Earnings Call Transcript: Q4 2025
Solid organic and acquisition-driven growth was achieved, with strong cash flow and resilient margins despite tariffs and FX headwinds. Guidance for 2026 anticipates 5%-8% organic growth and 20%-22% EBITDA margin, supported by efficiency gains and new product launches.
Embla Medical Earnings Call Transcript: Q4 2025
Solid organic sales growth and profitability were achieved in 2025, driven by strong performance in prosthetics and neuroorthotics, with robust cash flow and margin resilience despite FX and tariff headwinds. 2026 guidance targets 5%-8% organic growth and 20%-22% EBITDA margin.
Embla Medical hf: Interim Report Q4 and Full Year 2025
COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026 Interim Report Q4 and Full Year 2025 Sveinn Sölvason, President and CEO, comments: "We delivered solid sales in the fourth qua...
Embla Medical Earnings Call Transcript: Q3 2025
Q3 2025 saw 7% organic and 11% reported sales growth, led by double-digit gains in prosthetics and neuroorthotics, while patient care and bracing/supports lagged. EBITDA margin held at 22%, and full-year guidance for 5%-6% organic growth and 20%-21% EBITDA margin was reiterated.
Embla Medical Earnings Call Transcript: Q3 2025
Q3 2025 saw 7% organic sales growth, led by double-digit gains in prosthetics and new orthotics, with EBITDA margin at 22%. Guidance for 5%-6% organic growth and 20%-21% EBITDA margin is reiterated, while tariffs and internal changes impact patient care and bracing segments.
Embla Medical hf: Interim Report Q3 2025
COPENHAGEN, Denmark , Oct. 21, 2025 /PRNewswire/ -- Announcement no. 49/2025 Interim report Q3 2025 21 October 2025 Sveinn Sölvason, President and CEO, comments: "Sales in Q3 2025 amounted to USD 237...
Embla Medical hf: Embla Medical closes the majority share investment in Streifeneder ortho.production GmbH
Announcement no. 39/2025 29 August 2025 Reference is made to announcement no.
Embla Medical Earnings Call Transcript: Q2 2025
Q2 saw 7% revenue growth (5% organic) and a 21% EBITDA margin, with guidance narrowed to 5%-6% organic growth for the year. Strategic moves included the Streifeneder investment and a new U.S. reimbursement code for FIOR & GENTZ, while tariffs and U.S. healthcare changes pose ongoing risks.
Embla Medical Earnings Call Transcript: Q2 2025
Q2 saw 7% sales growth and a 21% H1 EBITDA margin, led by Prosthetics and Neuro orthotics, with EMEA outperforming and Americas expected to accelerate in H2. Guidance narrowed to 5–6% organic growth, and a strategic acquisition is pending approval.
Embla Medical hf: Interim Report Q2 2025
Announcement no. 33/2025 Interim report Q2 2025 22 July 2025 COPENHAGEN, Denmark , July 22, 2025 /PRNewswire/ -- Sveinn Sölvason, President and CEO, comments: "Sales in Q2 2025 amounted to USD 232 mil...
Embla Medical hf: Embla Medical signs agreement to invest in a majority share in Streifeneder ortho.production GmbH
Announcement no. 31/2025 17 July 2025 REYKJAVIK, Iceland and COPENHAGEN, Denmark , July 17, 2025 /PRNewswire/ -- Embla Medical (NASDAQ Copenhagen: EMBLA), a leading global provider of innovative mobil...
Embla Medical Transcript: Status Update
Navii, a new microprocessor knee, offers premium waterproofing and personalization at a standard price, targeting expanded user segments and differentiating from competitors. User trials show high satisfaction, and the market is expected to grow significantly, driven by expanded reimbursement and innovation.
Embla Medical Earnings Call Transcript: Q1 2025
Q1 saw 4% organic sales growth and a higher EBITDA margin, with strong EMEA and APAC performance offset by a slow start in the Americas. Guidance for 5%-8% organic growth and 19-20% EBITDA margin is maintained, but US market recovery is key to meeting targets.
Embla Medical Earnings Call Transcript: Q1 2025
Q1 2025 saw 4% organic sales growth to $203M, with EBITDA margin up to 18% and net profit rising 45% year-over-year. EMEA and APAC regions drove growth, while the Americas lagged due to lower patient volumes and reimbursement delays. Full-year guidance for 5%-8% organic growth and 20%-21% EBITDA margin is maintained.
Embla Medical Earnings Call Transcript: Q4 2024
Achieved solid organic growth and margin expansion in 2024, driven by new product launches, a key acquisition, and expanded U.S. reimbursement. 2025 guidance targets 5%-8% organic growth and higher margins, with balanced regional performance and resumed share buybacks.
Embla Medical Earnings Call Transcript: Q4 2024
Full-year organic sales grew 6% with strong EMEA and segment performance, while EBITDA margin improved to 20%. 2025 guidance targets 5%-8% organic growth and 20%-21% EBITDA margin, supported by new product launches and expanded U.S. Medicare coverage.
Embla Medical Transcript: ABGSC Investor Days
Embla Medical is expanding its global presence and product innovation, with strong growth in bionics and neuro orthotics, and a major boost expected from U.S. Medicare reforms. Financial performance remains robust, with ongoing margin improvements and strategic focus on emerging markets and operational efficiency.
Embla Medical Transcript: Status Update
Fior & Gentz, now part of a broader growth strategy, is expanding globally with innovative, custom orthotic solutions, leveraging a strong product pipeline and unique configurator tools. The business is highly scalable, maintains strong margins, and is focused on increasing market penetration and education.
Embla Medical Transcript: Status Update
Strong growth and margin expansion in 2024 were driven by strategic acquisitions, a shift to patient-centric care, and robust performance in key segments. U.S. Medicare's expanded reimbursement for bionics and new product launches set the stage for further growth in 2025.
Embla Medical Earnings Call Transcript: Q3 2024
Q3 2024 saw 7% organic sales growth, 22% EBITDA margin, and 58% net profit increase, led by strong EMEA and high-end prosthetics. U.S. Medicare's bionic knee coverage expansion is expected to gradually boost future growth, while APAC growth was mixed and bracing faced price pressure.
Embla Medical hf: Interim Report Q3 2024
Announcement no. 12/2024 Interim report Q3 2024 22 October 2024 COPENHAGEN, Denmark , Oct. 22, 2024 /PRNewswire/ -- Sveinn Sölvason, President and CEO, comments: "We delivered solid sales in the thir...
Embla Medical Transcript: Status Update
Medicare's recent coverage expansion is the largest in decades, granting more lower activity amputees access to advanced prosthetics and shifting many to higher functional categories. This creates immediate growth for Medicare patients and a medium to long-term opportunity as commercial payers follow suit.